Navigation Links
Robert Farrell Joins Bionovo's Board of Directors

EMERYVILLE, Calif., Jan. 5, 2012 /PRNewswire/ -- Bionovo Inc. (NASDAQ: BNVI) announced today the appointment of Robert E. Farrell, J.D., to the Company's Board of Directors.  Mr. Farrell will also serve as an independent director and member of the Company's Audit and Compensation committees. Mr. Farrell has more than 20 years of financial management experience in the pharmaceutical and biotech industries.


"We are very excited to add Mr. Farrell to our Board of Directors," stated Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "Bob has extensive experience with public markets, financial regulatory issues and with the structuring of corporate partnerships in the pharmaceutical and life science industries.  We believe Mr. Farrell's background in these areas will prove valuable to Bionovo's current efforts, and we are quite excited to have access to his expertise."

From 1996-2009, Mr. Farrell held the positions of Executive Vice President and CFO of Titan Pharmaceuticals, Inc. and was appointed President and CEO of Titan in December 2008, a position that he held through 2009.  Prior to Titan Pharmaceuticals, from 1991-1996, Mr. Farrell served as Corporate Group Vice President and CFO of Fresenius USA, a pharmaceutical manufacturing and medical device company focused on the treatment of end-stage renal disease.

Mr. Farrell holds an undergraduate degree from the University of Notre Dame and received his J.D. degree from the University of California.

"I believe that Menerba, and Bionovo's pipeline of other drugs and innovative technologies, will provide safer treatments for unmet needs in the areas of women's health and cancer. I look forward to working with the Company as it advances its drug development programs," said Mr. Farrell.

About Bionovo

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Robert W. Baird Conference
2. Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Childrens Health Care
3. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
4. Robert Cantu Appointed Vice President of Pierpoint International
5. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
6. Danaher to Present at Robert W. Baird Industrial Conference
7. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
8. CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer
9. Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development
10. Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition
11. Healthplace America Engages Robert A. Yungk to Provide Services as Chief Strategy Officer
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):